A team led by VHIO Principal Investigator and OPTIMISTICC scientist Dr. Paolo Nuciforo has found an association between the persistence of Fusobacterium nucleatum in rectal tumors of LARC patients after chemotherapy and higher rates of rectal cancer relapse. This discovery, published recently in the Annals of Oncology, indicates that Fusobacterium can serve as a prognostic biomarker that will help physicians better determine and adjust courses of treatment for LARC. This study is described in more detail in VHIO’s press release.
Kimmie Ng and Marios Giannakis publish a perspective “A Common Cancer at an Uncommon Age”
By 2030 colorectal cancer will be the leading cause of cancer deaths in individuals aged 20-49. Young-onset CRC differs from average age onset. Young-onset disease is often more aggressive, presents on the left side of the colon rather than the right, and often...
